JP2011521647A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011521647A5 JP2011521647A5 JP2011511791A JP2011511791A JP2011521647A5 JP 2011521647 A5 JP2011521647 A5 JP 2011521647A5 JP 2011511791 A JP2011511791 A JP 2011511791A JP 2011511791 A JP2011511791 A JP 2011511791A JP 2011521647 A5 JP2011521647 A5 JP 2011521647A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- antibody
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13053908P | 2008-05-30 | 2008-05-30 | |
| US13039408P | 2008-05-30 | 2008-05-30 | |
| US13039508P | 2008-05-30 | 2008-05-30 | |
| US61/130,539 | 2008-05-30 | ||
| US61/130,395 | 2008-05-30 | ||
| US61/130,394 | 2008-05-30 | ||
| PCT/US2009/045365 WO2009155015A1 (en) | 2008-05-30 | 2009-05-28 | Anti-flt3 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011521647A JP2011521647A (ja) | 2011-07-28 |
| JP2011521647A5 true JP2011521647A5 (https=) | 2012-03-15 |
Family
ID=41092183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011511791A Withdrawn JP2011521647A (ja) | 2008-05-30 | 2009-05-28 | 抗ｆｌｔ３抗体 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20090297529A1 (https=) |
| EP (1) | EP2300500A1 (https=) |
| JP (1) | JP2011521647A (https=) |
| KR (1) | KR20110004455A (https=) |
| CN (1) | CN102046659A (https=) |
| AR (1) | AR071891A1 (https=) |
| AU (1) | AU2009260517B2 (https=) |
| BR (1) | BRPI0912173A2 (https=) |
| CA (1) | CA2726522A1 (https=) |
| CL (1) | CL2009001277A1 (https=) |
| EA (1) | EA201071421A1 (https=) |
| IL (1) | IL209142A0 (https=) |
| MX (1) | MX2010013144A (https=) |
| NZ (1) | NZ588791A (https=) |
| PE (1) | PE20091963A1 (https=) |
| TW (1) | TWI374032B (https=) |
| WO (1) | WO2009155015A1 (https=) |
| ZA (1) | ZA201008024B (https=) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR071891A1 (es) * | 2008-05-30 | 2010-07-21 | Imclone Llc | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |
| HUE045270T2 (hu) | 2010-01-05 | 2019-12-30 | Inst Nat Sante Rech Med | FLT3 receptor anatgonisták fájdalom rendellenességek kezelésére |
| US20130156764A1 (en) * | 2010-03-12 | 2013-06-20 | The Johns Hopkins University | Neutralization of flt3 ligand as a leukemia therapy |
| MX353958B (es) * | 2011-09-22 | 2018-02-07 | Amgen Inc | Proteinas de union al antigeno cd27l. |
| US20150064203A1 (en) * | 2012-03-08 | 2015-03-05 | Japan Science And Technology Agency | Anticancer agent |
| US20170335281A1 (en) | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| JP2017528433A (ja) | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| EP3268038B1 (en) * | 2015-03-09 | 2021-05-05 | Agensys, Inc. | Antibody drug conjugates (adc) that bind to flt3 proteins |
| EP3286211A1 (en) | 2015-04-23 | 2018-02-28 | Novartis AG | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
| EP3569244A1 (en) | 2015-09-23 | 2019-11-20 | CytoImmune Therapeutics, LLC | Flt3 directed car cells for immunotherapy |
| FI3380620T3 (fi) | 2015-11-23 | 2024-08-01 | Novartis Ag | Optimoituja lentiviruksen siirtovektoreita ja niiden käyttötapoja |
| RU2018127657A (ru) | 2015-12-30 | 2020-01-31 | Новартис Аг | Виды терапии на основе иммуноэффекторных клеток с улучшенной эффективностью |
| EP3432924A1 (en) | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
| CA3025516A1 (en) * | 2016-05-27 | 2017-11-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Flt3-specific chimeric antigen receptors and methods using same |
| IL263744B2 (en) | 2016-06-17 | 2023-11-01 | Magenta Therapeutics Inc | Compositions and methods for the depletion of cd117 plus cells |
| WO2018111340A1 (en) | 2016-12-16 | 2018-06-21 | Novartis Ag | Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells |
| AU2017382883B2 (en) | 2016-12-21 | 2024-07-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies specific for FLT3 and uses thereof |
| EP3571230A4 (en) | 2017-01-20 | 2020-12-16 | Magenta Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR DELETION OF CD137 + CELLS |
| ES2912408T3 (es) | 2017-01-26 | 2022-05-25 | Novartis Ag | Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos |
| CN110582509A (zh) | 2017-01-31 | 2019-12-17 | 诺华股份有限公司 | 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症 |
| WO2018160731A1 (en) | 2017-02-28 | 2018-09-07 | Novartis Ag | Shp inhibitor compositions and uses for chimeric antigen receptor therapy |
| JP2020519665A (ja) | 2017-05-17 | 2020-07-02 | アンセルム（アンスティテュト ナショナル ド ラ サンテ エ ド ラ ルシェルシュ メディカル） | オピオイドによる痛みの処置を改善する為のｆｌｔ３阻害剤 |
| SG10202108528QA (en) * | 2017-06-02 | 2021-09-29 | Pfizer | Chimeric antigen receptors targeting flt3 |
| MY201312A (en) | 2017-06-02 | 2024-02-16 | Pfizer | Antibodies specific for flt3 and their uses |
| WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
| US20200165344A1 (en) * | 2017-07-31 | 2020-05-28 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and flt3 |
| WO2019081983A1 (en) | 2017-10-25 | 2019-05-02 | Novartis Ag | CD32B TARGETING ANTIBODIES AND METHODS OF USE |
| RU2020116579A (ru) | 2017-10-25 | 2021-11-25 | Новартис Аг | Способы получения клеток, экспрессирующих химерный антигенный рецептор |
| US20210179709A1 (en) | 2017-10-31 | 2021-06-17 | Novartis Ag | Anti-car compositions and methods |
| WO2019164930A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| EP3801769A1 (en) | 2018-05-25 | 2021-04-14 | Novartis AG | Combination therapy with chimeric antigen receptor (car) therapies |
| WO2019237035A1 (en) | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| SG11202104352XA (en) | 2018-12-18 | 2021-05-28 | Boehringer Ingelheim Io Canada Inc | Flt3 agonist antibodies and uses thereof |
| KR20210106437A (ko) | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
| CN113490528B (zh) | 2019-02-15 | 2024-12-03 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| CA3123519A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| WO2020210719A1 (en) * | 2019-04-10 | 2020-10-15 | Elevatebio Management, Inc. | Flt3-specific chimeric antigen receptors and methods of using the same |
| TW202110873A (zh) * | 2019-04-30 | 2021-03-16 | 美商聖堤生物科技股份有限公司 | 嵌合受體及其使用方法 |
| JP7489407B2 (ja) | 2019-05-21 | 2024-05-23 | ノバルティス アーゲー | Ｃｄ１９結合分子及びその使用 |
| AU2020283742A1 (en) * | 2019-05-24 | 2021-09-16 | Elixiron Immunotherapeutics (hong Kong) Limited | Anti-CSF1R antibodies, IL10 fusion proteins, and uses thereof |
| PE20221316A1 (es) * | 2019-10-15 | 2022-09-07 | Dragonfly Therapeutics Inc | Proteinas que se unen a nkg2d, cd16 y flt3 |
| AU2020366000A1 (en) * | 2019-10-15 | 2022-05-12 | Dragonfly Therapeutics, Inc. | Antibodies targeting FLT3 and use thereof |
| BR112022011902A2 (pt) | 2019-12-20 | 2022-09-06 | Novartis Ag | Terapias de combinação |
| CN115768463A (zh) * | 2020-02-21 | 2023-03-07 | 哈普恩治疗公司 | Flt3结合蛋白及使用方法 |
| JP7525109B2 (ja) * | 2020-03-18 | 2024-07-30 | 学校法人金沢医科大学 | Ｃｄ１３５＋細胞を含む医薬組成物 |
| CN115715297A (zh) | 2020-04-14 | 2023-02-24 | 法国施维雅药厂 | 抗flt3抗体和组合物 |
| AU2021256053A1 (en) | 2020-04-17 | 2022-11-10 | City Of Hope | FLT3-targeted chimeric antigen receptor modified cells for treatment of FLT3-positive malignancies |
| US20230174614A1 (en) | 2020-04-30 | 2023-06-08 | Terry J FRY | Multispecific anti-flt3 chimeric antigen receptors |
| JP7512394B2 (ja) | 2020-05-06 | 2024-07-08 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質 |
| JP2023529211A (ja) | 2020-06-11 | 2023-07-07 | ノバルティス アーゲー | Ｚｂｔｂ３２阻害剤及びその使用 |
| KR20230027056A (ko) | 2020-06-23 | 2023-02-27 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 |
| CN111808821B (zh) * | 2020-06-24 | 2022-06-14 | 南方医科大学珠江医院 | Flt3-nkg2d双靶点car-t的构建与制备 |
| JP7819176B2 (ja) | 2020-08-03 | 2026-02-24 | ノバルティス アーゲー | ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| CA3198447A1 (en) | 2020-11-13 | 2022-05-19 | Novartis Ag | Combination therapies with chimeric antigen receptor (car)-expressing cells |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| WO2022229853A1 (en) | 2021-04-27 | 2022-11-03 | Novartis Ag | Viral vector production system |
| AU2022330106A1 (en) * | 2021-08-16 | 2024-03-21 | Hemogenyx Pharmaceuticals Llc | Anti-flt3 antibodies, cars, car t cells and methods of use |
| US12129302B2 (en) | 2021-08-25 | 2024-10-29 | Ibio, Inc. | Anti-CD-25 antibody |
| WO2023105087A1 (en) * | 2021-12-10 | 2023-06-15 | Tubulis Gmbh | Novel flt3 antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof in combination with tyrosine kinase inhibitors |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| AU2023369684A1 (en) | 2022-10-26 | 2025-04-17 | Novartis Ag | Lentiviral formulations |
| PE20252789A1 (es) | 2023-05-24 | 2025-12-22 | Kumquat Biosciences Inc | Compuestos heterociclicos y usos de estos |
| WO2026052513A1 (en) * | 2024-09-09 | 2026-03-12 | Adcytherix Sas | Antibody-drug conjugates comprising an flt3 binding antibody |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| ATE74118T1 (de) | 1987-04-03 | 1992-04-15 | Hermann Hofmann | Verfahren zum kompostieren von organischen stoffen und vorrichtung zur durchfuehrung dieses verfahrens. |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| WO1989009622A1 (en) | 1988-04-15 | 1989-10-19 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
| AU4128089A (en) * | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5185438A (en) | 1991-04-02 | 1993-02-09 | The Trustees Of Princeton University | Nucleic acids encoding hencatoporetic stem cell receptor flk-2 |
| US5367057A (en) * | 1991-04-02 | 1994-11-22 | The Trustees Of Princeton University | Tyrosine kinase receptor flk-2 and fragments thereof |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| AU4025193A (en) | 1992-04-08 | 1993-11-18 | Cetus Oncology Corporation | Humanized C-erbB-2 specific antibodies |
| US7537932B1 (en) * | 1993-05-19 | 2009-05-26 | Schering Corporation | Antibodies that bind purified mammalian FLT3 ligands |
| US5554512A (en) | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
| AU7832394A (en) | 1993-09-08 | 1995-03-27 | Imclone Systems Incorporated | Monoclonal antibodies that recognize flk-2 receptors and the isolation of primitive hematopoietic stem cell populations |
| US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
| DE19608769C1 (de) * | 1996-03-07 | 1997-04-10 | Univ Eberhard Karls | Antikörper BV10A4H2 |
| US6084060A (en) | 1996-12-09 | 2000-07-04 | Imclone Systems Incorporated | Composition and method for preserving progenitor cells |
| DE19727814C1 (de) * | 1997-06-30 | 1998-10-01 | Univ Eberhard Karls | Anitkörper 4G8B4B12 |
| KR20010071271A (ko) | 1998-05-15 | 2001-07-28 | 존 비. 랜디스 | 방사선 및 성장 인자 수용체 티로신 키나아제 억제제에의한 사람 종양의 치료법 |
| US6999122B1 (en) * | 1999-07-22 | 2006-02-14 | Minolta Co., Ltd. | Solid-state logarithmic image sensing device |
| CA2450793A1 (en) | 2001-06-20 | 2002-12-27 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| JPWO2005094823A1 (ja) | 2004-03-30 | 2007-08-16 | 協和醗酵工業株式会社 | Ｆｌｔ−３阻害剤 |
| US8227455B2 (en) | 2005-04-18 | 2012-07-24 | Rigel Pharmaceuticals, Inc. | Methods of treating cell proliferative disorders |
| CA2687896A1 (en) | 2007-06-05 | 2008-12-18 | Yale University | Antibody directed against the d4 ig-like domain of the kit receptor |
| AR071891A1 (es) * | 2008-05-30 | 2010-07-21 | Imclone Llc | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |
-
2009
- 2009-05-22 AR ARP090101855A patent/AR071891A1/es not_active Application Discontinuation
- 2009-05-25 CL CL2009001277A patent/CL2009001277A1/es unknown
- 2009-05-25 PE PE2009000733A patent/PE20091963A1/es not_active Application Discontinuation
- 2009-05-28 EP EP09767327A patent/EP2300500A1/en not_active Ceased
- 2009-05-28 BR BRPI0912173A patent/BRPI0912173A2/pt not_active IP Right Cessation
- 2009-05-28 NZ NZ588791A patent/NZ588791A/en not_active IP Right Cessation
- 2009-05-28 CN CN2009801189357A patent/CN102046659A/zh active Pending
- 2009-05-28 MX MX2010013144A patent/MX2010013144A/es active IP Right Grant
- 2009-05-28 EA EA201071421A patent/EA201071421A1/ru unknown
- 2009-05-28 US US12/473,295 patent/US20090297529A1/en not_active Abandoned
- 2009-05-28 JP JP2011511791A patent/JP2011521647A/ja not_active Withdrawn
- 2009-05-28 KR KR1020107026790A patent/KR20110004455A/ko not_active Ceased
- 2009-05-28 CA CA2726522A patent/CA2726522A1/en not_active Abandoned
- 2009-05-28 WO PCT/US2009/045365 patent/WO2009155015A1/en not_active Ceased
- 2009-05-28 US US12/994,956 patent/US20110091470A1/en not_active Abandoned
- 2009-05-28 AU AU2009260517A patent/AU2009260517B2/en not_active Expired - Fee Related
- 2009-06-01 TW TW098118092A patent/TWI374032B/zh not_active IP Right Cessation
-
2010
- 2010-09-27 US US12/890,793 patent/US8071099B2/en not_active Expired - Fee Related
- 2010-11-04 IL IL209142A patent/IL209142A0/en unknown
- 2010-11-09 ZA ZA2010/08024A patent/ZA201008024B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011521647A5 (https=) | ||
| JP2009102444A5 (ja) | 二次性骨腫瘍の治療のための抗PDGFRα抗体 | |
| AR080698A1 (es) | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e | |
| JP2020500016A5 (https=) | ||
| IL261585A (en) | Antigen-binding human proteins that bind beta-klotho, fgf receptors and their complexes | |
| AR071891A1 (es) | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) | |
| IL302078A (en) | Anti-CCR8 monoclonal antibodies and their uses | |
| AR127344A2 (es) | Conjugados anticuerpo-fármaco que comprenden agonistas de sting | |
| JP2018127467A5 (https=) | ||
| JP2020500538A5 (https=) | ||
| AR073770A1 (es) | Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden | |
| JP2012510461A5 (https=) | ||
| JP2013529183A5 (https=) | ||
| JP2020518599A5 (https=) | ||
| JP2012505912A5 (https=) | ||
| AR061115A1 (es) | Anticuerpos anti- interleuquina 18 (il-18) | |
| JP2009106306A5 (ja) | 抗PDGFRα抗体 | |
| JP2012136541A5 (https=) | ||
| JP2010535713A5 (https=) | ||
| RU2019102009A (ru) | Специфические антитела к pd-l1 и способы их применения | |
| JP2010270124A5 (https=) | ||
| PE20160994A1 (es) | Compuestos al receptor-3 del factor de crecimiento del fibroblasto (fgfr3) y metodos de tratamiento | |
| JP2012523417A5 (https=) | ||
| JP2021501579A5 (https=) | ||
| JP2020521797A5 (https=) |